{"id":821074,"date":"2025-03-04T06:53:14","date_gmt":"2025-03-04T11:53:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/"},"modified":"2025-03-04T06:53:14","modified_gmt":"2025-03-04T11:53:14","slug":"eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/","title":{"rendered":"Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">DEER PARK, Ill., March  04, 2025  (GLOBE NEWSWIRE) &#8212; Eton Pharmaceuticals, Inc. (\u201cEton\u201d or the &#8220;Company\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will hold a virtual Investor Day and report fourth quarter 2024 financial results on Tuesday, March 18, 2025, beginning at 10:00 a.m. ET (9:00 a.m. CT).<\/p>\n<p>In addition to discussing fourth quarter 2024 financial results, the Investor Day event will offer investors an in-depth look at Eton\u2019s rare disease portfolio and financial outlook after a transformational six months. The company will share its view of the long-term market opportunity and commercial strategy for the recently acquired Increlex\u00ae and Galzin\u00ae products, as well as provide an update on its adrenal insufficiency franchise, Alkindi Sprinkle\u00ae and ET-400, and the associated market landscape. In addition, the company will highlight recent developments within its pipeline of attractive rare disease product candidates. Featured speakers include Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, David Krempa, Chief Business Officer, and Ipek Erdogan-Trinkaus, Chief Commercial Officer. Audience members will have the opportunity to ask questions following the prepared remarks.<\/p>\n<p>To participate, please\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3Y8qT1_jG8EOK9CK0E1IVPp7vdZAvUIRbVxheGf26nJY1NtMBd-O8F6LfaMe5gNW0v0u3IEYyFPMvjK2JkLTRh9trSkM3TQNTJNX28L0Psvxy3GdrBGp6xciFRJANHEe4CzXSeNdRxj9urH-3YuJuw==\" rel=\"nofollow\" target=\"_blank\">click here<\/a> to register. An archived webcast will be available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=trYtB5HbjT_6ai9Cbez08RhRFMTWOVoImO1sA5ITFF4YFKPaX8m4VEJBL_TRvbiFj8lMHSGYEsTH-f3mtucAeCFarWNNfIwcGwNzizS_eMYHohSP3t6pf1a3tGg0VqD_\" rel=\"nofollow\" target=\"_blank\">Investors section of Eton\u2019s website<\/a> approximately two hours after the completion of the event and for 30 days thereafter.<\/p>\n<p>\n        <strong>About Eton Pharmaceuticals<\/strong>\n      <\/p>\n<p>Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX\u00ae, ALKINDI SPRINKLE\u00ae, GALZIN\u00ae, PKU GOLIKE\u00ae, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: ET-400, ET-600, Amglidia\u00ae, and ZENEO\u00ae hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton\u2019s business strategy, Eton\u2019s plans to develop and commercialize its product candidates, the safety and efficacy of Eton\u2019s product candidates, Eton\u2019s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton\u2019s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as \u201cbelieves,\u201d \u201canticipates,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cwill,\u201d \u201cgoal,\u201d \u201cpotential\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton\u2019s development programs and financial position are described in additional detail in Eton\u2019s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n<p>\n        <strong>Investor Relations:<\/strong><br \/>\n        <br \/>Lisa M. Wilson, In-Site Communications, Inc.<br \/>T: 212-452-2793<br \/>E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0pa1YWhR3l6niRTP5qjPS1u-7Rngbb_hcYwtc45lWQMZYLiRAaFK87KYKxt2kUACmYZVdVbGGe7GZuPmGMDPlfxzzZSa2CDncYgYWSGR_z8=\" rel=\"nofollow\" target=\"_blank\">lwilson@insitecony.com<\/a><\/p>\n<p>Source: Eton Pharmaceuticals, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODM5NCM2Nzg4ODIwIzIxMjI5ODQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTVjZTA4OWEtMjAzNC00MzEyLTgyM2EtMDU5NWFmYmU0ZWFjLTExMzQ1NTU=\/tiny\/Eton-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) &#8212; Eton Pharmaceuticals, Inc. (\u201cEton\u201d or the &#8220;Company\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will hold a virtual Investor Day and report fourth quarter 2024 financial results on Tuesday, March 18, 2025, beginning at 10:00 a.m. ET (9:00 a.m. CT). In addition to discussing fourth quarter 2024 financial results, the Investor Day event will offer investors an in-depth look at Eton\u2019s rare disease portfolio and financial outlook after a transformational six months. The company will share its view of the long-term market opportunity and commercial strategy for the recently acquired Increlex\u00ae and Galzin\u00ae products, as well as provide an &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-821074","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) &#8212; Eton Pharmaceuticals, Inc. (\u201cEton\u201d or the &#8220;Company\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will hold a virtual Investor Day and report fourth quarter 2024 financial results on Tuesday, March 18, 2025, beginning at 10:00 a.m. ET (9:00 a.m. CT). In addition to discussing fourth quarter 2024 financial results, the Investor Day event will offer investors an in-depth look at Eton\u2019s rare disease portfolio and financial outlook after a transformational six months. The company will share its view of the long-term market opportunity and commercial strategy for the recently acquired Increlex\u00ae and Galzin\u00ae products, as well as provide an &hellip; Continue reading &quot;Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-04T11:53:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODM5NCM2Nzg4ODIwIzIxMjI5ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025\",\"datePublished\":\"2025-03-04T11:53:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/\"},\"wordCount\":625,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODM5NCM2Nzg4ODIwIzIxMjI5ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/\",\"name\":\"Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODM5NCM2Nzg4ODIwIzIxMjI5ODQ=\",\"datePublished\":\"2025-03-04T11:53:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODM5NCM2Nzg4ODIwIzIxMjI5ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODM5NCM2Nzg4ODIwIzIxMjI5ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/","og_locale":"en_US","og_type":"article","og_title":"Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 - Market Newsdesk","og_description":"DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) &#8212; Eton Pharmaceuticals, Inc. (\u201cEton\u201d or the &#8220;Company\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will hold a virtual Investor Day and report fourth quarter 2024 financial results on Tuesday, March 18, 2025, beginning at 10:00 a.m. ET (9:00 a.m. CT). In addition to discussing fourth quarter 2024 financial results, the Investor Day event will offer investors an in-depth look at Eton\u2019s rare disease portfolio and financial outlook after a transformational six months. The company will share its view of the long-term market opportunity and commercial strategy for the recently acquired Increlex\u00ae and Galzin\u00ae products, as well as provide an &hellip; Continue reading \"Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-04T11:53:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODM5NCM2Nzg4ODIwIzIxMjI5ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025","datePublished":"2025-03-04T11:53:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/"},"wordCount":625,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODM5NCM2Nzg4ODIwIzIxMjI5ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/","name":"Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODM5NCM2Nzg4ODIwIzIxMjI5ODQ=","datePublished":"2025-03-04T11:53:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODM5NCM2Nzg4ODIwIzIxMjI5ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODM5NCM2Nzg4ODIwIzIxMjI5ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-results-on-march-18-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=821074"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821074\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=821074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=821074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=821074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}